MHRA-100443-PIP01-22-M01 (update)

Key Facts

Active Substance
Active Substance:
  • BARICITINIB
Invented Name
  • Olumiant
  • Olumiant
PIP Number MHRA-100443-PIP01-22-M01 (update)
Pharmaceutical form(s)
  • Film-coated tablet
  • Oral suspension
Therapeutic area
Therapeutic area:
  • Immunology -Rheumatology-Transplantation
Conditions / Indications
Conditions / Indications:
  • Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, ankylosing spondylarthritis, psoriatic arthritis and juvenile idiopathic arthritis)
Route(s) of administration
Route(s) of administration:
  • Oral use
PIP applicant
Decision Type
Decision Type
PM: decision on the application for modification of an agreed paediatric investigation plan.
Compliance Check
Compliance Check
Yes
Compliance Check Decision Date
Compliance opinion date
15/12/2022
Compliance Check Procedure Number
Compliance procedure number
MHRA-100443-PIP01-22-M01-C1

Decision Document

Decision Document Decision Document on a Paediatric Investigation Plan (PIP):BARICITINIB.pdf
Published Date 25/05/2023